Selank 10mg – Synthetic Tuftsin Analog for Anxiolytic & Cognitive Research

Our pharmaceutical-grade Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) represents a synthetic analog of the endogenous immunomodulatory peptide tuftsin, engineered to cross the blood-brain barrier and modulate central nervous system function with pronounced anxiolytic and nootropic properties. Developed at the Institute of Molecular Genetics in Russia, this heptapeptide has emerged as a unique research tool for investigating anxiety disorders, stress resilience, and cognitive enhancement without the sedation, dependency, or motor impairment associated with benzodiazepine or barbiturate mechanisms. Unlike [DSIP Spray](#], which targets delta-sleep induction and HPA axis modulation through distinct pathways, Selank operates primarily through enkephalinase inhibition and GABAergic tone modulation, offering a peptide-based approach to emotional regulation that preserves alertness and cognitive clarity.

As a member of the “Russian peptide” family alongside Semax, Selank demonstrates immunomodulatory properties inherited from its parent molecule tuftsin (a tetrapeptide cleaved from IgG heavy chains), while acquiring enhanced neurotropic characteristics through the C-terminal proline-glycine-proline extension. This structural modification facilitates BBB penetration and enkephalinase resistance, allowing Selank to increase endogenous enkephalin levels and modulate GABA-A receptor subunit expression. When reconstituted with [bacteriostatic water](#], this lyophilized preparation enables investigation into the “opioidergic tone” hypothesis of anxiety, examining whether stabilization of met-enkephalin signaling can produce sustained anxiolysis without the tolerance or withdrawal phenomena observed with direct GABA-A agonists.

For neuropharmacology researchers studying the intersection of immune function and emotional behavior, or investigating nootropic strategies distinct from cholinergic or catecholaminergic stimulants, Selank offers a mechanistically unique peptide that bridges psychoneuroimmunology and affective neuroscience.

 Mechanisms of Action: Enkephalins, GABA & BDNF

Selank (molecular weight 751.89 Da) exerts its anxiolytic and cognitive effects through multiple convergent mechanisms that distinguish it from traditional anxiolytics and structurally dissimilar peptides like [BPC-157](#].

Enkephalinase Inhibition:
The primary mechanism involves inhibition of enkephalin-degrading enzymes (aminopeptidases and neutral endopeptidases), increasing the half-life of endogenous met-enkephalin in the brain. These endogenous opioid peptides bind to delta-opioid receptors to produce anxiolytic effects without the respiratory depression or euphoria associated with mu-opioid agonists. Research indicates Selank can increase enkephalin levels in the hippocampus and amygdala—structures critical for emotional memory and fear processing—providing a “tone” of opioidergic inhibition over anxious responding rather than acute sedation.

GABAergic Modulation:
Unlike benzodiazepines that directly agonize GABA-A receptors, Selank appears to modulate receptor subunit composition (specifically increasing alpha-1 and gamma-2 subunits) and enhance GABA release presynaptically. This indirect modulation preserves the physiological rhythm of GABAergic inhibition rather than imposing continuous hyperpolarization, explaining the lack of sedation or cognitive impairment despite robust anxiolytic efficacy. Research compares this mechanism to the sleep-promoting but non-sedating effects of [DSIP Spray](#], though Selank specifically targets anxiety circuits rather than sleep architecture.

BDNF & Neuroplasticity:
Selank upregulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus, particularly the BDNF Val66Met polymorphism carriers who typically show reduced activity-dependent secretion. This neurotrophic effect supports synaptic plasticity, long-term potentiation, and neurogenesis—mechanisms underlying both antidepressant effects and cognitive enhancement. Unlike [CJC-1295](#], which influences cognition indirectly through growth hormone-mediated metabolic effects, Selank provides direct neurotrophic support through BDNF transcriptional activation.

Immunomodulatory Heritage:
Retaining tuftsin’s immunological properties, Selank modulates T-helper cell balance (Th1/Th2) and IL-6 production, potentially explaining its efficacy in psychoneuroimmunology models where anxiety correlates with inflammatory cytokine elevation. This dual CNS-immune action distinguishes it from purely neurological peptides.

 Research Applications & Therapeutic Models

Generalized Anxiety & Panic Disorders:
The primary application for Selank involves research into generalized anxiety disorder (GAD), social anxiety, and panic disorder models. Studies demonstrate reduced anxiety indices in elevated plus maze, open field, and Vogel conflict tests without the muscle relaxation or motor incoordination seen with benzodiazepines. Research focuses on “performance anxiety” paradigms where subjects must maintain cognitive function under stress—Selank improves both emotional stability and task performance, unlike anxiolytics that impair cognition.

Post-Traumatic Stress Disorder (PTSD):
Research investigates Selank’s ability to modulate fear extinction and prevent stress-induced behavioral pathology. By enhancing enkephalinergic tone in the amygdala-prefrontal cortex circuit, Selank may facilitate the extinction of conditioned fear responses without the emotional blunting associated with SSRI or SNRI treatment. Studies compare efficacy to [BPC-157](#], which addresses PTSD through structural hippocampal repair and HPA axis normalization, while Selank targets the opioidergic emotional regulation systems.

Cognitive Enhancement & Nootropic Research:
Beyond anxiety, Selank demonstrates nootropic properties including improved memory consolidation, attention span, and learning speed in animal models. Research examines its utility in cognitive decline prevention, attention-deficit disorders, and recovery from traumatic brain injury. The mechanism—BDNF upregulation and synaptic protein synthesis—differs from stimulant-based cognition enhancement, offering sustainable improvements without tolerance or rebound effects.

Withdrawal & Addiction Research:
Selank shows promise in mitigating benzodiazepine and alcohol withdrawal symptoms through GABAergic stabilization and stress reduction. Research investigates whether Selank can prevent kindling phenomena during withdrawal or reduce drug-seeking behavior in addiction models by normalizing the stress-response systems that drive relapse.

Immune-Mediated Anxiety:
For psychoneuroimmunology research, Selank addresses the “inflammatory hypothesis” of depression and anxiety, where elevated IL-6 and TNF-alpha correlate with anxious phenotypes. By modulating cytokine production while simultaneously treating CNS anxiety circuits, Selank offers a unified approach to stress-induced immunological and behavioral dysregulation.

 Product Specifications & Molecular Characteristics

• Chemical Name: Selank; L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-proline
• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (heptapeptide)
• Parent Compound: Synthetic analog of Tuftsin (Thr-Lys-Pro-Arg) with C-terminal Pro-Gly-Pro extension
• Molecular Formula: C₃₃H₅₇N₁₁O₁₁
• Molecular Weight: 751.89 g/mol
• Total Content: 10mg per vial (lyophilized powder)
• Structure: Linear heptapeptide with proline-rich C-terminus
• Purity: ≥99% (HPLC verified)
• Appearance: White to off-white fluffy lyophilized powder
• Solubility: Highly soluble in aqueous solutions (water, saline, bacteriostatic water)
• Storage: -20°C stable (lyophilized), 2-8°C after reconstitution
• Reconstituted Stability: 14-21 days at 2-8°C when prepared with preservatives

Quality Verification:
Each batch analyzed via mass spectrometry for correct molecular weight (752.4 [M+H]+) and absence of truncation products (particularly the parent tuftsin tetrapeptide). Biological activity confirmed through enkephalinase inhibition assays or behavioral pharmacology testing in anxiety models (elevated plus maze).

 Reconstitution, Administration & Research Protocols

Preparation Guidelines:
Reconstitute Selank 10mg with 2-5ml of bacteriostatic water to create a 2-5mg/ml stock solution. As a small, hydrophilic heptapeptide, Selank dissolves readily in neutral aqueous solutions without requiring acidic buffers or organic co-solvents. The proline-rich C-terminus confers resistance to aminopeptidase degradation, though sterile technique remains essential to prevent microbial contamination.

Route of Administration:
Research employs multiple routes depending on study objectives:

• Intranasal: Preferred for CNS targeting due to direct nose-to-brain transport via olfactory pathway, similar to [DSIP Spray](#]. Rapid onset (10-20 minutes) and enhanced BBB penetration.
• Subcutaneous: Standard for systemic immunomodulatory studies and sustained anxiolytic effects.
• Intraperitoneal: Common in rodent anxiety pharmacology research.

Dosing Parameters:
Typical research concentrations range from 100-300 mcg/kg body weight in animal models, with intranasal doses often 10-50% of parenteral requirements due to enhanced CNS bioavailability. Chronic administration studies (4-6 weeks) investigate sustained anxiolytic effects without tolerance development—a key distinction from benzodiazepines.

Timing Considerations:
For acute anxiety research, administer 30-60 minutes prior to behavioral testing. For chronic stress resilience studies, once or twice daily administration maintains stable enkephalinergic tone. Unlike [CJC-1295](#] which requires specific timing relative to meals or sleep, Selank demonstrates flexible administration windows.

 Comparative Analysis: Selank vs. Alternative Compounds

Selank vs. Semax:
Both are Russian-developed cognitive enhancers, but Selank targets anxiety and emotional regulation through enkephalin/GABA modulation, while Semax acts primarily through BDNF/trkB activation and dopaminergic modulation without significant anxiolytic properties. Selank is the choice for anxiety-with-cognition research; Semax for pure cognitive enhancement.

Selank vs. DSIP:
While [DSIP Spray](#] modulates sleep architecture and HPA axis stress responses through delta-wave induction, Selank specifically targets the opioidergic and GABAergic circuits of anxiety without inducing sleep. Research comparing these peptides investigates whether daytime anxiety (Selank) and nighttime sleep restoration (DSIP provide complementary stress resilience strategies.

Selank vs. BPC-157:
Both address stress-related pathology but through distinct mechanisms. [BPC-157](#] repairs structural damage (gastric ulcers, tendon injuries, neuronal degeneration) through angiogenesis and growth factor modulation. Selank prevents and treats the functional/emotional consequences of stress through neurochemical modulation. Combination research investigates whether structural repair (BPC-157) plus emotional resilience (Selank) offers superior outcomes in chronic stress models than either alone.

Selank vs. Traditional Anxiolytics:
Unlike benzodiazepines (GABA-A agonists) which cause sedation, motor impairment, and dependency, Selank produces anxiolysis without these side effects through indirect GABA modulation and enkephalinase inhibition. Unlike SSRIs which require weeks for efficacy, Selank shows acute anxiolytic effects within hours, making it valuable for research into rapid-acting antidepressant/anxiolytic mechanisms.

 Safety Considerations & Research Limitations

Sedation vs. Anxiolysis:
Researchers must distinguish between the absence of anxiety (anxiolysis) and the presence of sedation (CNS depression). Selank produces the former without the latter, requiring different behavioral endpoints than benzodiazepine research (e.g., activity levels should remain normal, unlike the hypolocomotion seen with diazepam).

Immune Interactions:
Due to its tuftsin heritage, Selank modulates immune function. Research must account for potential interactions in models of infection, autoimmunity, or cancer, where immunomodulation could confound primary anxiety or cognitive endpoints.

Enkephalin Specificity:
While increasing enkephalins produces anxiolysis, excessive opioidergic tone could theoretically affect pain perception or reward processing. Research monitors for analgesic effects or interaction with opioid receptors that might confound anxiety-specific outcomes.

 Frequently Asked Research Questions

How does Selank differ from benzodiazepines?
Selank produces anxiolysis without direct GABA-A agonism, avoiding sedation, muscle relaxation, and dependency. It enhances natural GABAergic tone and enkephalin levels rather than imposing continuous receptor activation, preserving cognitive function and motor coordination.

Can Selank be combined with cognitive enhancers?
Yes, research often combines Selank with cholinergic or dopaminergic nootropics, as its anxiolytic properties can reduce the jitteriness associated with stimulant-based cognitive enhancers. Unlike [CJC-1295](#], which affects metabolism broadly, Selank specifically targets anxiety-cognition interactions.

Is intranasal delivery effective for Selank?
Highly effective. Like [DSIP Spray](#], the small heptapeptide structure facilitates transmucosal absorption and olfactory nerve transport to the CNS, achieving brain concentrations comparable to or exceeding parenteral administration while reducing systemic exposure.

Does Selank cause tolerance?
Research indicates Selank does not produce the tolerance seen with benzodiazepines or the withdrawal phenomena associated with GABA-A modulators. Its mechanism—enhancing endogenous enkephalin tone—appears to be sustainable without receptor downregulation.

How quickly does it work?
Onset of anxiolytic effects typically occurs within 30-60 minutes of administration (faster with intranasal delivery), with peak effects at 1-2 hours. This rapid onset distinguishes it from SSRIs and makes it suitable for acute anxiety research protocols.

Selank is a research compound in lyophilized powder form for laboratory research, testing, and analytical applications.

• Compound: Selank

• Quantity: 5 mg

• Purity: ≥99% (HPLC Certified)

• Form: Lyophilized powder

• Appearance: White to off-white powder

• Solubility: Soluble in laboratory-grade sterile water

• COA: Included in product image gallery